Marshall Wace North America’s Palvella Therapeutics PVLA Stock Holding History

Marshall Wace North America’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$4.51M	Buy	+10,895	New	+$3.79M	0.02%	539
2020 Q1	–	Sell	-2,422	Closed	-$701K	–	1656
2019 Q4	$701K	Buy	+2,422	New	+$671K	﹤0.01%	772
2018 Q3	–	Sell	-2,011	Closed	-$816K	–	1431
2018 Q2	$816K	Sell	2,011 -2,473	-55%	-$1.18M	﹤0.01%	985
2018 Q1	$2.45M	Buy	+4,484	New	+$2.78M	0.01%	756
2017 Q4	–	Sell	-214	Closed	-$103K	–	1650
2017 Q3	$103K	Buy	+214	New	+$91.4K	﹤0.01%	1202

Other funds holding PVLA

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's PVLA Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Palvella Therapeutics (PVLA) in Q3 2021: 10,895 shares worth $4.51M. The stake represents 0.02% of the portfolio and ranks #539 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in PVLA as recently as Q4 2019.

Marshall Wace North America first reported a position in PVLA in Q3 2017 and has held it in 5 quarters since. 75 funds tracked by Wall St. Rank hold PVLA as of Q3 2021.

Marshall Wace North America held 10,895 shares of Palvella Therapeutics worth $4.51M as of Q3 2021.
Palvella Therapeutics was a new Marshall Wace North America position in Q3 2021.
Palvella Therapeutics made up 0.02% of Marshall Wace North America's portfolio in Q3 2021, its #539 holding.
Marshall Wace North America first reported a position in Palvella Therapeutics in Q3 2017 and has held it in 5 quarters since.
75 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.